

## Helix Announces Peptide Purchase Agreements

*Aug 07, 2007 - Bothell, Washington*

Helix BioMedix Inc. (OTC Bulletin Board: HXBM), a developer of bioactive peptides, today announced that it has entered into a peptide purchase agreement with Peptisyntha, Inc., a peptide manufacturer.

The agreement includes a commitment by Helix to purchase peptides over an eighteen-month period for total consideration of \$234,000. In addition, Helix recently completed a smaller purchase of peptides from the same supplier for total consideration of \$64,000.

"These purchases represent the largest peptide purchase commitment in Helix's history and reflect our expectation that our marketing partners will sell increased quantities of peptide-based products over the next eighteen months," commented R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix. "These peptides are included in our partners' products, which are currently marketed through a growing network of significant regional and national retailers including Walgreens, CVS, Longs, Rite Aid, Whole Foods, and Wild Oats."

### **About Helix BioMedix, Inc.**

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically applied products, which offer the health, beauty and safety benefits of advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology.

Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners.

More information about the company and its proprietary peptides may be found on the company's website at [www.helixbiomedix.com](http://www.helixbiomedix.com).

### **Forward Looking Statements**

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including

pre-clinical and clinical studies, realize increased sales of its peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at [www.sec.gov](http://www.sec.gov). Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

**Contacts:**

Shelton Group Investor Relations

Investor Contact:

Ryan Bright, 972-239-5119 X 159

[rbright@sheltongroup.com](mailto:rbright@sheltongroup.com)

or

Helix BioMedix, Inc.

R. Stephen Beatty, 425-402-8400

President and CEO

[sbeatty@helixbiomedix.com](mailto:sbeatty@helixbiomedix.com)